Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 258-265

  Anderson, Peter L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antiretroviral therapy; Clinical pharmacology; HIV; Nucleoside analog; Phosphorylation; Safety

Indexed keywords

ABACAVIR; ALCOHOL DEHYDROGENASE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; APRICITABINE; ATAZANAVIR; BRECANAVIR; DARUNAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLYCOPROTEIN P; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; NUCLEOSIDE ANALOG REVERSE TRANSCRIPTASE INHIBITOR; ORGANIC ANION TRANSPORTER; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

CELL COMPARTMENTALIZATION; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DRUG HALF LIFE; DRUG SAFETY; ENZYME PHOSPHORYLATION; FEMALE GENITAL SYSTEM; GENETIC POLYMORPHISM; GLUCURONIDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOSPADIAS; KIDNEY CLEARANCE; LACTIC ACIDOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOSPHORYLATION; PLASMA; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

EID: 42049095513     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f85dc1     Document Type: Review

References (64)

1. Back DJ, Burger DM, Flexner CW, et al. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr 2005; 39(suppl 1):S1-23, quiz S24-S25.
2. Flynn PM, Rodman J, Lindsey JC, et al. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother 2007; 51:3516-3522. This is an intensive analysis of zidovudine-triphosphate concentrations during once and twice daily dosing.
3. Ruane PJ, Richmond GJ, DeJesus E, et al. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300mg twice/day in therapy-naive patients infected with human immunodeficiency virus. Pharmacotherapy 2004; 24:307-312.
4. Aweeka FT, Rosenkranz SL, Segal Y, et al. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS 2006; 20:1833-1841. This is a comprehensive comparison of zidovudine-phosphates between the sexes and according to sex hormone therapy in women.
5. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-2168.
6. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38:1541-1547.
7. Moyle G, Fletcher C, Higgs C, et al. An open-label, two-period crossover, pharmacokinetic (PK) study of abacavir (ABC) and its intracellular anabolite carbovir triphosphate (CBV-TP) following 600mg once daily and 300 mg twice-daily administration of abacavir in HIV-infected subjects [abstract 13]. In: Program and Abstracts of the 8th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest, Hungary. Geneva, Switzerland: International AIDS Society; 2007. http://www.hivpresentation.com/ index.cfm?vID=B047C197-E0C4-D510-0C6CB4B4485B6AD9 [Accessed 13 February 2008].
8. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45:254-260. Strong evidence is presented for exaggerated risk for NRTI-associated life-threatening lactic acidosis in women compared with men in an African setting.
9. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685-708.
10. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004; 38:743-753.
11. Anderson PL, Zheng JH, King T, et al. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS 2007; 21:1849-1854. New evidence is presented that zidovudine-triphosphate and lamivudine-triphosphate concentrations are different according to cell type in vivo. Also, the triphosphates were quantified in CD4 purified cells in vivo, which is the first such analysis.
12. Durand-Gasselin L, Da Silva D, Benech H, et al. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob Agents Chemother 2007; 51:2105-2111. New evidence is presented that tenofovir-diphosphate concentrations are of equal amounts in RBCs as in PBMCs. This could be important for drug-drug interactions potentially mediated in RBCs (e.g. didanosine, ribavirin).
13. Gao WY, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993; 91:2326-2333.
14. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent antihuman immunodeficiency virus activity and anabolic phosphorylation of 20,30-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269:12633-12638.
15. Robbins BL, Srinivas RV, Kim C, et al. Antihuman immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42:612-617.
16. Saavedra-Lozano J, McCoig CC, Cao Y, et al. Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2004; 48:2825-2830.
17. Villarroya F, Domingo P, Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (Lond) 2007; 31:1763-1776.
18. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8:F1-F5.
19. Wattanagoon Y, Na Bangchang K, Hoggard PG, et al. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers. Antimicrob Agents Chemother 2000; 44:1986-1989.
20. Turriziani O, Butera O, Gianotti N, et al. Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. AIDS 2005; 19:473-479.
21. Holdich T, Shiveley LA, Sawyer J. Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2007; 51:2943-2947. This remarkable study demonstrates a major intracellular interaction between lamivudine-triphosphate and apricitabine-triphosphate, but no interaction between the drugs was apparent in plasma.
22. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125. This is the first report that a potential antagonistic interaction exists between ribavirin and abacavir, whereby abacavir may reduce the anti-HCV activity of ribavirin.
23. Vispo E, Barreiro P, Maida I, et al. Abacavir-containing HAART reduces the chances for sustained virological response to pegylated-interferon plus ribavirin in HIV-Infected patients with chronic hepatitis C [abstract P1948]. In: Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago, Illionois. Washington, District of Columbia, USA: American Society for Microbiology; 2007. http://www.natap.org/2007/ICAAC/ICAAC_22.htm [Accessed 13 February 2008].
24. Pineda JA, Mira JA, Gil Ide L, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-1354. In this large retrospective dataset, the authors detected differences in HCV response according to whether HIV was under treatment and according to certain NRTI backbones in the HIV regimen.
25. Margot NA, Miller MD. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir Ther 2005; 10:343-348.
26. Balzarini J, Lee CK, Herdewijn P, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′- dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991; 266:21509-21514.
27. Hoggard PG, Veal GJ, Wild MJ, et al. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995; 39:1376-1378.
28. Aweeka FT, Kang M, Yu JY, et al. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med 2007; 8:288-294. This article and that by Rodriguez-Torres et al. [29] quantify the interaction between HCV therapy and NRTI-triphosphates in vivo. The results are negative for an interaction, which contradicts what has been shown in vitro. This is an important lesson that in-vitro studies do not always predict in-vitro effects.
29. Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother 2005; 49:3997-4008.
30. Gilead Sciences: Viread® (tenofovir): product information. Foster City, California, USA: Gilead Sciences; 2007.
31. Ofotokun I, Chuck SK, Binongo JN, et al. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol 2007; 47:970-977.
32. Kurowski M, Walli RK, Breske A, et al. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. AIDS 2007; 21:1368-1370.
33. Luber A, Slowinski D, Andrews M, Olson K, Peloquin C, Pakes GE, Pappa K, Shelton MJ. Steady-state pharmacokinetics of tenofovir and fosamprenavir after once daily tenofovir with unboosted or ritonavir-boosted twice daily fosamprenavir in healthy volunteers. In: Program and Abstracts of the 8th International Congress on Drug Therapy in HIV Infection; 12-16 November 2006; Glasgow, UK. Macclesfield, Cheshire, UK: Thomson Gardiner-Caldwell Group Limited; 2006.
34. Chittick GE, Zong J, Blum MR, et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother 2006; 50:1304-1310.
35. Tibotec, Inc.: Prezista (darunavir): product information. Raritan, New Jersey, USA: Tibotec, Inc.; 2006.
36. Boehringer Ingelheim Pharmaceuticals: Aptivus® (tipranavir): product information. Ridgefield, Connecticut, USA: Boehringer Ingelheim Pharmaceuticals; 2006.
37. Bristol-Myers Squibb Co.: Reyataz® (atazanavir): product information. Princeton, New Jersey, USA: Bristol-Myers Squibb Co.; 2007.
38. Merck & Co., Inc.: Isentress® (raltegravir): product information. Whitehouse Station, New Jersey, USA: Merck & Co., Inc; 2007.
39. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83:265-272. This is one of the first in-vivo drug interaction studies involving tenofovir that addressed the potential mechanism for the interaction between renally eliminated tenofovir and liver-metabolized drugs (in this case inhibition of tenofovir renal clearance).
40. Kiser JJ, Aquilante CL, Anderson PL, et al.: Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. JAIDS 2008 (in press).
41. Ford SL, Murray S, Anderson M, Ng-Cashin J, Johnson M, Shelton MJ. Tenofovir renal clearance decreased following co-administration with brecanavir/ritonavir [abstract 38]. In: Program and Abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon, Portugal. Utrecht, The Netherlands: Virology Education BV; 2006.
42. Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007; 71:619-627.
43. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50:3297-3304.
44. Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51:3498-3504.
45. Rotger M, Colombo S, Furrer H, et al. Does tenofovir influence efavirenz pharmacokinetics? Antivir Ther 2007; 12:115-118.
46. Kiser J. Investigational HIV drugs. Curr Opin HIV AIDS 2008.
47. Waters LJ, Moyle G, Bonora S, et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther 2007; 12:825-830. New information is presented that indicates that ritonavir-boosted protease inhibitors lower plasma abacavir.
48. Shaik N, Giri N, Pan G, Elmquist WF. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 2007; 35:2076-2085.
49. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre and postexposure prophylaxis. AIDS 2007; 21:1899-1907. This report provides critical information on NRTI penetration into the female genital tract, which is important given the interest in using NRTIs as pre-exposure and post-exposure prophylaxis. The study evaluated first dose and steady-state data and AUCs.
50. Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006; 20:553-560. This is an intensive evaluation of abacavir plasma pharmacokinetics in late pregnancy versus postpartum.
51. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74-78. This is an example of better tolerability and long-term lipoatrophic outcomes in TDF/emtricitabine recipients versus zidovudine/lamivudine.
52. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-147. Example of better long-term lipoatrophic outcomes for abacavir recipients versus stavudine.
53. Milinkovic A, Martinez E, Lopez S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12:407-415.
54. Owen A, Khoo SH. Pharmacogenetics of antiretroviral agents. Curr Opin HIV AIDS 2008;
55. Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007; 59:591-593.
56. Grant RM, Wainberg MA. Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis 2006; 194:874-876.
57. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27. These are the first clinical data for the much-hyped TDF for pre-exposure prophylaxis indication. No major toxicities were observed during the 1-year study. No differences in HIV transmission were observed in TDF recipients versus placebo.
58. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to nonnucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-1705. This paper identifies an interesting new potential indication for TDF/emtricitabine as a single dose in mothers along with nevirapine to prevent nevirapine resistance. Additional research of this strategy is warranted, given the results of this study.
59. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004; 18:2442-2444.
60. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, Distric of Columbia, USA: Department of Health and Human Services; 2006. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 13 February 2008].
61. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
62. Meng Q, Olivero OA, Fasco MJ, et al. Plasma and cellular markers of 3′-azido-3′-dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs. Environ Mol Mutagen 2007; 48 (3-4):307-321. This important work elucidates the potential effects of NRTIs on cellular DNA in vivo. It should be noted that this article is one of several articles devoted to this topic, which appear together in this journal issue.
63. Watts DH. Treating HIV during pregnancy: an update on safety issues. Drug Saf 2006; 29:467-490.
64. Watts DH, Li D, Handelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2007; 44:299-305.